EP1805501A2 - Appareil et procede de dosage a ecoulement lateral de precision - Google Patents

Appareil et procede de dosage a ecoulement lateral de precision

Info

Publication number
EP1805501A2
EP1805501A2 EP05811958A EP05811958A EP1805501A2 EP 1805501 A2 EP1805501 A2 EP 1805501A2 EP 05811958 A EP05811958 A EP 05811958A EP 05811958 A EP05811958 A EP 05811958A EP 1805501 A2 EP1805501 A2 EP 1805501A2
Authority
EP
European Patent Office
Prior art keywords
flow
sample
fluid
mixing chamber
flow cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05811958A
Other languages
German (de)
English (en)
Inventor
Thomas R. Witty
Robert Case
Scott Castanon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FasTraQ Inc
Original Assignee
FasTraQ Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/990,762 external-priority patent/US20060079003A1/en
Priority claimed from US10/991,331 external-priority patent/US20060078471A1/en
Application filed by FasTraQ Inc filed Critical FasTraQ Inc
Publication of EP1805501A2 publication Critical patent/EP1805501A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/42—Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
    • B01F25/43—Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/30—Micromixers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0409—Moving fluids with specific forces or mechanical means specific forces centrifugal forces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0457—Moving fluids with specific forces or mechanical means specific forces passive flow or gravitation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics

Definitions

  • the present invention relates generally to methods and systems for analyzing fluid samples and, more specifically, to methods and systems for using a flow channel to control sample fluid incubation.
  • Blood and other body fluid tests are important diagnostic methods in patient care and treatment. The reliability and the accuracy of the tests are critical in correctly diagnosing the patient and administrating proper treatment.
  • the Food and Drug Administration (FDA) has established numerous quality standards for the various blood or body fluid tests. Monitoring the test process is beneficial in producing reliable and accurate test results.
  • One way of monitoring the test process is periodically performing the monitoring test on standard test samples.
  • the monitoring test results are compared with expected results to verify the accuracy of the test processes or correct the test instrument or process when appropriate.
  • the test processes are assumed to generate consistent result between the monitoring tests.
  • test process Another way of monitoring the test process is including standard test samples in the test process. This approach is suitable for a test process that performs tests on multiple samples. The test results on the standard test samples are compared with expected results to verify the accuracy of the test processes. In this approach, the test processes on real samples are assumed to generate result consistent with those on standard test samples.
  • test apparatus it would be advantageous to have an apparatus and a method for monitoring a test process that is simple, and reliable. It is desirable for the test apparatus to be compact and capable of generating test results fast thereby meeting the need of the emergency rooms. It would be of further advantage for the apparatus and method to be easily adaptable for monitoring different test processes. Additionally, some tests require specific preparation of the fluid sample prior to testing. Some may desire certain incubation time before the fluid sample is tested. It would be advantageous to provide an apparatus and a method for properly preparing the sample for testing.
  • An object of the present invention is to provide improved methods and systems for monitoring a test processes in real time.
  • Another object of the present invention is to provide methods and systems for monitoring test processes that performs a comparison of a timing of the introduction, and the exit of a sample to and from a measurement chamber, in order to confirm of a point in time of a valid reaction of the sample in the measurement chamber.
  • Yet another object of the present invention is to provide methods and systems for monitoring test processes that directly monitors the flow of a sample and a reagent into a measurement chamber.
  • a further object of the present invention is to provide methods and systems for monitoring test processes in a flow cell that in real time sense the flow a sample or a reagent without relying on information that originates outside the flow cell.
  • Yet another object of the present invention is provide methods and systems to provide in a flow device a capture area on an assay of sufficient size to sequentially immobilize the sample analyte at the saturation threshold and beyond, as it migrates along the capture area.
  • a flow cell configured to be fluidly coupled to a fluid moving source and utilized with a monitor device
  • the flow cell includes a housing, a mixing chamber and a flow channel.
  • the flow channel is sized to provide for movement of liquid from the mixing chamber by non-capillary action.
  • a matrix is positioned at a distal end of the flow channel. The matrix contains a compound that will react with the sample to create a change detectable by the monitor device.
  • a fluid path extends from the mixing chamber to the flow channel and to the matrix to bring sample fluid to the matrix for the detection of analyte levels.
  • a flow cell system in another embodiment, includes a housing, a mixing chamber and a flow channel.
  • the flow channel is sized to provide for movement of liquid from the mixing chamber by non-capillary action.
  • a monitoring device is coupled to the matrix.
  • a fluid moving source is coupled to the flow channel.
  • a matrix is coupled to a distal end of the flow channel and contains a compound that will react with the sample to create a change detectable by the monitor device.
  • a fluid path extends from the mixing chamber to the flow channel and to the matrix to bring sample fluid to the matrix for the detection of analyte levels.
  • a flow cell is configured to be fluidly coupled to a fluid moving source and used with a monitor device.
  • the flow cell includes a housing, mixing chamber, flow channel and a matrix.
  • the matrix is positioned in the mixing chamber.
  • a fluid path extends from the mixing chamber to the flow channel.
  • the flow channel is sized to provide for non-capillary fluid flow.
  • a test device in another embodiment, has a non- microporous mixing chamber.
  • a flow channel is coupled to the mixing chamber.
  • a matrix is in fluid communication with the flow channel.
  • the matrix contains a compound that will react with the sample to create a change detectable by a monitor device.
  • a fluid path extends from the mixing chamber to the flow channel and to the matrix to bring sample fluid to the matrix for detection of analyte levels.
  • a method for analyzing a sample for the presence of an analyst.
  • the sample is introduced into a test device that includes a non-microporous mixing chamber, flow channel and a matrix.
  • the sample flows from the mixing chamber through the flow channel to the matrix which contains a compound that will react with the sample to create a change detectable by a monitor device.
  • a method for extending the dynamic range from which a concentration of at least a portion of an analyte present in a sample is determined.
  • a plurality of samples, each containing a known analyte-label conjugate concentration, are reached with at least one capture area in a detection zone of a flow device.
  • the at least one capture area is homogeneously saturated along at least a portion of its length and width dimensions with a known amount of a binding moiety.
  • At least a portion of the capture area is scanned to produce a series of intensity signals corresponding to an immobilized analyte- label conjugate unique to a concentration of analyte in each sample.
  • a dose response curve is created from the unique series of detection signals for each immobilized sample analyte-label conjugate concentration against position on the capture area.
  • An overall assay response value is calculated for each dose response curve.
  • Overall assay response values are plotted against the known analyte-label conjugate concentrations to create a calibration curve.
  • a concentration of an analyte in a test sample containing an unknown concentration analyte is ascertained by determining where the test sample assay response falls on the calibration curve.
  • a diagnostic assay kit is provided for extending the dynamic range for the concentration of analyte or fragments thereof in a sample.
  • a solid-phase substrate has at least one capture area homogeneously saturated with a known amount of binding moiety for binding with the sample analyte-label conjugate.
  • a detector detects the labeled amount of captured analyte or fragments thereof, on the at least one capture area and produces a series of detection signals along at least a portion of a length of the at least one capture area to form a continuous dose response curve.
  • the at least one capture area is dimensioned to capture the sample analyte-label conjugate with the binding moiety in an amount effective to immobilize any unbound analyte-label conjugate until the detection signal decreases below a horizontal asymptote.
  • a forced flow assay device is provided that is capable of extending the dynamic range for the concentration of analyte or fragments thereof in a sample.
  • An inlet receives a sample containing an analyte.
  • At least one flow channel is in fluid communication with the inlet.
  • the at least one flow channel has at least one reagent area with a labeled binding partner.
  • the at least one flow channel is dimensioned to provide an incubation period for reacting an effective amount of labeled binding partner with the sample analyte to form an analyte-label conjugate.
  • a detection zone is in fluid communication with the at least one flow channel.
  • the detection zone has at least one capture area saturated with a binding moiety and is dimensioned to provide an wide assay range of enhanced sensitivity. At least a portion of a length of the capture area is in optical communication with the detector.
  • a fluid control device is configured to provide forced fluid flow throughout the forced flow assay device.
  • Figure 1 illustrates an apparatus for performing a test on a fluid sample in accordance with the present invention.
  • Figure 2 shows a cross-sectional view of one embodiment of a flow device according to the present invention.
  • Figure 3 is a perspective view of another embodiment of a flow device according to the present invention.
  • Figures 4 and 5 show cross-sectional views of the device shown in Figure 3.
  • Figure 6 is a perspective view of yet another embodiment of a flow device according to the present invention.
  • Figure 7 is a perspective view of a still further another embodiment of a flow device according to the present invention.
  • Figure 8 shows a cross-sectional view of the device shown in Figure 7.
  • Figure 9 illustrates another embodiment of a flow device according to the present invention.
  • Figure 10 illustrates an embodiment of the present invention, similar to that of Figure 9, but with multiple capture areas.
  • Figure 11 illustrates a series of curves indicating what happens when the capture reagent is fully saturated.
  • the present invention provides a flow cell configured to be coupled to a fluid moving source, including but not limited to a pump. An open flow channel is provided where fluid is moved at a precise rate.
  • Fluid in the open flow channel does not move on its own without action of a fluid moving source.
  • the open flow channel can be sized so that it does not have capillarity flow and does not draw a sample forward without the flow provided by the fluid moving source.
  • Flow cell can be disposable flow cell and mate to a cartridge that delivers the sample from a vacutainer through a sample introduction port. An operator can attach the vacutainer to a larger cartridge to begin the flow.
  • an assay device in one embodiment, includes a large capture area saturated with a binding moiety for enhancing the sensitivity in detecting a sample containing large concentrations of analyte.
  • the assay device that can include at least one large capture area that is homogeneously saturated with a binding moiety to provide a wide range of sensitivity and/or precision in the detection of a sample containing high concentrations of analyte.
  • the phase "binding moiety" is used interchangeably with the phrase "capture reagent”. These terms denote a particulate or molecular binding partner affixed or non- diffusively attached within or upon a solid phase (e.g., matrix, pad, microparticles, etc.) to form a capture area.
  • the immobilized capture reagent is incapable of being solubilized or otherwise removed from the solid phase. The capture reagent is used to capture or immobilize the migrating sample-label conjugate.
  • a solid-phase assay is provided that has an enlarged capture area saturated with capture reagent. This provides that a high proportion of the analyte is bound, and increases the assay sensitivity.
  • the saturation threshold that is the capture reagent is fully saturated, and the detection signals plotted on dose response curve are at the maximum, that is the horizontal asymptote of the curve, the larger capture area continues to immobilize excess analyte. This allows sequential saturation of the capture region beyond the saturation threshold.
  • Vacuum can be used to pull the sample through the flow cell. Pressurize can be utilized to push the sample through. In one embodiment the pressure is about 1 psi.
  • a standard flow detector can be utilized for sensing when a sample, including but not limited to blood, has reached the flow cell, since there may be a variation in head space in the vacutainer tube. The process of inserting on the large cartridge neutralizes the pressure. It starts at atmospheric pressure so there is not any unexpected movement in or out of the tube. Because the headspace can vary (depending on a full draw or partial draw), when that headspace needs to be compressed before starting movement, there can be a variable time lag. A flow detector can be used to account for any variation in timing to get the fluid flowing.
  • Background signal can be removed.
  • Sample can continue flowing into a matrix to deplete a solid phase label (so no more label is left to detect).
  • the sample can be used as a wash or the sample can be followed with a chaser wash to lower the background noise.
  • a system uses a dry reagent in a fluid moving source, metered system.
  • Embodiments of the present invention can use a flow cell with a dry reagent, where the flow cell is used with the fluid moving source system.
  • fluorescent beads can be utilized because they are more stable than a fluorescent molecule.
  • a hydrophobic membrane can be used to contain an immobilized antibody.
  • a method is provided that brings reagents into proximity. The incubation time is controlled by the flow rates. Incubation time can be controlled without varying the structure of the device used. Changing the flow rate will change the incubation times. Temperature can also be controlled on the flow cell. Thermal devices can be placed along or adjacent the flow path to regulate temperature.
  • Figure 1 is a schematic diagram of an apparatus 10 for performing a test on a fluid sample in accordance with the present invention.
  • apparatus 10 is used for performing tests on blood samples or other fluids.
  • the blood tests may be hematology tests, chemistry tests or immunology tests that provide valuable information in diagnosing such conditions as viral infection, bacterial infection, blood loss, heart attack, pregnancy, hormonal disorders, metabolic status, neuronal damage, cancer, cellular function, genetic information, electrolyte balance, blood clotting, drug monitoring, toxicology and the like.
  • apparatus 10 is capable of monitoring the blood test process on an effective real time basis without relying on extrinsic information such as the test results of standard samples or secondary process monitoring such as motor position detection.
  • Apparatus 10 includes a flow cell holder 11 for holding flow cell 12. During a test, the sample flows through flow cell 12. In one embodiment, a reactive antibody specific to an analyte in the test is coated on the surface of flow cell 12 during the production of flow cell 12. For each test, a new flow cell 12 is placed on flow cell holder 11. A sensing of a sample or a reagent is provided in real time without relying on information that originates outside flow cell 12. The external monitoring information can include a mechanical, electrical or photo event within apparatus 10 external to flow cell 12.
  • the mechanical information can include fluid moving source information such as pump driver movement, pneumatic movement of air, valve encoder rotation within apparatus 10, electrical sensing of a sample in a sampling device such as by a needle or other capillary, and the like.
  • fluid moving source information such as pump driver movement, pneumatic movement of air, valve encoder rotation within apparatus 10, electrical sensing of a sample in a sampling device such as by a needle or other capillary, and the like.
  • in real time means a frequency of measurement to insure that the reaction in a selected time period has taken place.
  • the selected time period can be 10% or less of the overall time period step or process in the reaction.
  • in real time can be in the range of 1 second to 1 minute, and the like, depending on the analyte and process involved.
  • Flow cell 12 can also include at least one reactive binding partner, including but not limited to an antibody and the like.
  • the reactive binding partner can be any material that can specifically bind the analyte directly or indirectly.
  • the reactive antibody can be present on a surface of flow cell 12, in a flow path of flow cell 12 (which can be in the form of on a membrane, on particles immobilized in the flow path, and the like.
  • the reactive binding partner can immobilized in a flow path of flow cell 12. Samples and/or reagents are into flow cell 12,
  • the reagent can be a calibrant, a fluid containing reactant, a fluid not containing a reactant, a sample, and the like.
  • one or more dyes can be included and mixed with the reactive binding partner. Electrical and other means of sensing can be aided with other non-interfering additives.
  • the inclusion of dye base line image data with different characteristics can be utilized. By way of illustration, and without limitation, the different characteristics can be different in intensity, frequency, magnetic field or other measurable property.
  • Apparatus 10 also includes an energy source 14 that can be positioned adjacent to flow cell holder 11
  • Energy source 14 can be a variety of different sources including but not limited to electrical, mechanical, optical (both coherent and incoherent light), RF, resistive heating, ultrasound, magnetic, and the like.
  • a sensor 18 is positioned to receive an output from flow cell 12.
  • energy source 14 When energy source 14 is optical, energy source 14 can be a LED, LED array and coherent light source. Suitable LED's include but are not limited to, white, red, green, blue source, and the like. An electromagnetic field can also be utilized. As a light source, energy source 14 can be positioned to project an incident light beam 15 towards flow cell 12. In response to the activity in flow cell 12, a light beam 17 is reflected from flow cell 12. More than one light source 14 can be used. Multiple light sources 14 can be employed to monitor different test processes using image data formed from different light beams.
  • flow cell 12 includes a measurement chamber 19.
  • a monitor device 21 directly monitors and produces a signal indicative of an introduction and an exit of at least one of a sample or a reagent to and from measurement chamber 19.
  • Logic resources 23 receive the signal and performs a comparison of a timing of the introduction and the exit of the sample to and from measurement chamber 19. This produces a confirmation of a point in time of a valid reaction of the sample in measurement chamber 19. The validity of the reaction is defined by the juxtapositioning of two or more reagents in a timeframe that has been determined to be sufficient for full and complete reaction.
  • Flow cell 12 includes an inlet, an outlet and a channel coupled to measurement chamber 19.
  • Inlet is configured to provide for introduction of the sample into the inlet by a variety of means including but not limited to, laminar flow, absorption, with the use of a pumping force (displacement, either positive or negative pressure) gravity, centrifugal force, pneumatic movement, and the like.
  • flow cell 12 includes bibulous materials. At least a portion of the flow of flow cell 12 can be induced by the bibulous material and is open to the atmosphere.
  • Flow cell 12 can also include non-bibulous materials.
  • the non-bibulous materials include a surface that has measurement chemistry and a second surface that is filled to the first surface. The second surface provides a window viewable by the sensor, optically or electronically.
  • sensors 18 can be utilized, including but not limited to a, photo sensor, charge coupled device, photo detector or array, PMT, CMOS, and the like.
  • Sensor 18 can be coupled to a digital image processing circuit. Sensor 18 is used to detect changes of the sample in measurement chamber 19. Such optical changes include but are not limited to, light reflection characteristics, light absorption characteristics, and light fluorescence characteristics. Electrical changes include but are not limited to conductance, capacitance, impedance, magnetic disturbances, and the like, hi one specific embodiment, sensor 18 is a charge coupled device (CCD) photo detector array coupled to a digital image processing circuit 25. Sensor 18 may also include a light beam focusing lens in front of the CCD photo detectors 18.
  • CCD charge coupled device
  • Energy source 14 produces an output of energy that interacts with measurement chamber 19.
  • Sensor 18 is positioned to receive an output from flow cell 12.
  • the output can be light intensity, a measurement of wavelength, a measurement of electric capacitance, a measurement of conductivity, impedance and/or magnetic field, and the like.
  • Monitor device 21 can include energy source 14 and/or sensor 18. Monitor device 21 can directly monitor a progress of events inside measurement chamber 19. This progress of events in measurement chamber 19 includes but is not limited to, sample introduction, calibrant introduction, sample wash out, calibrant displacement, reagent introduction, and the like. In one embodiment, the preceding in the prior sentence occur in a determined order and timing sequence that is dependent on the assay and sensor type.
  • monitor device 21 provides an indication of a response of the sample to a mechanical change of apparatus 10.
  • a mechanical change can include, but is not limited to, movement of a pump to create a flow of sample or reagent, pneumatic movement, movement of a reaction area in measurement chamber 19, movement of measurement chamber 19, a mechanical response relative to a secondary reaction in measurement chamber 19, sensing of a fluid entrance or displacement in the chamber and the like.
  • monitor device 21 detects changes in measurement chamber 19, and in response to the changes, determines if there is a sufficient amount of at least one of sample, reagent, calibrant, and the like in measurement chamber 19.
  • Logic resources 23 can implement a variety of different QC protocols for apparatus 10 including but not limited to, optical measurement to assure wetting of a strip test area at a selected time, optical measurement to assure wetting of a strip test area in measurement chamber 19 at a selected time following application of pressure to a sample pressurization, optical measurement of flow path to assure sample movement to specific point in a flow path at predetermined time from sample pressurization, optical measurement of a flow path to assure sample removal from a specific point in a flow path and replaced by a diluent at a predetermined time from diluent pressurization, optical measurement of an assay cell in measurement chamber 19, optical measurement of an assay cell in measurement chamber 19 to assure that diluted sample arrives at a selected measurement region and at a selected time from mixed sample pressurization, electrical measurement of an assay cell to assure that a calibrant has sufficiently filled measurement chamber 19, electrical measurement of an assay cell to assure that a calibrant has sufficiently filled measurement chamber 19 by a selected time from calibrant pressurization, electrical measurement of the assay
  • the flow cell 12 may be fluidically coupled to a fluid moving device, including but not limited to * such as but not limited to a pump to push fluid through the flow cell.
  • fluid may be "pulled” through the flow cell through the use of suction pump or vacuum * to draw fluid in such a manner.
  • the flow cell 12 may be formed to fit within a larger cartridge 44 (shown in phantom).
  • the flow cell 50 includes a sample introduction port 52 for receiving sample fluid.
  • the introduction port 52 may or may not have a shaft portion 54.
  • Fluid received from the port 52 will be received in a chamber 56.
  • the chamber 56 may be a solid phase label mixing chamber with or without a matrix 58.
  • the matrix 58 may contain labeled reagent for binding with the sample fluid.
  • the binding agent may be on the chamber wall or in some embodiments, it may be in the matrix which may be a glass fiber structure. Glass fiber may be used for the immobilized, solid phase antibody.
  • the glass fiber allows the use of a larger surface area and it may be easier to force the sample through that type of structure.
  • the fluid contact can be extended by stopping the flow or mixing enhanced by increasing the rate or flow through a tortuous path in order to maximize sample/label mixing interaction.
  • a solid-phase assay is utilized that has an increased density of capture reagent sites (i.e., binding moiety) that increase the dynamic range by increasing the density of the capture reagent present on a solid-phase substrate
  • a diagnostic assay kit is provided for extending the dynamic range for the concentration of analyte or fragments in a sample.
  • a solid-phase substrate is provided with at least one capture area homogeneously saturated with a known amount of binding moiety for binding with the sample analyte-label conjugate.
  • a detector detects the labeled amount of captured analyte, or fragments, present on the capture area. The detector produces a series of detection signals along the length of the capture area to form continuous dose response curve.
  • the capture area is dimensioned to effectively capture the sample analyte-label conjugate with the binding moiety in an amount effective to immobilize any unbound analyte-label conjugate until the detection signal decreases below the horizontal asymptote. This provides enhanced assay sensitivity.
  • the phase "dynamic range” and “pathological range” are used interchangeably herein to refer to the range between the maximum and minimum assay responses for an analyte.
  • the dynamic range can be achieved by a variety of different devices including but not limited to, a test strip, a microtiter plate, microsphere, or microparticle, and the like.
  • separation of the cells from whole blood before flowing into flow cell is performed.
  • non cell containing samples including but not limited to serum, plasma, urine, CSF and the like, are utilized.
  • the flow cell 50 includes a precision dimensioned flow channel 60 that receives fluid from the chamber 56 at a rate a rate precisely controlled by force applied by the fluid moving source which can be speed, hi one embodiment of the present invention, precision control results in less than a 10% variation in flow rate and thus a transit time through the precision flow channel 60 based on pumping mechanism control, Precision control can be achieved with devices and schemes that control the flow rate, the force that is applied to a fluid, and the like.
  • the flow channel 60 leads to a flow control chamber 62.
  • fluid sample flows into an immobilized antibody matrix 64.
  • the matrix 64 is coupled to a sample overflow chamber 66.
  • a vent or exit port 68 can be provided and used to provide suction to draw or pull fluid so that it flows through the flow cell.
  • a clear film window 70 may be used to cover the precision flow channel 60 and the matrix 64. The clear window allows for fluorescence or other indicator from the matrix 64 to be detected. It will be appreciated that the other indicators utilized can include, but are not limited to, color, magnetic property change, chemi-luminescence and the like.
  • the entire matrix 64 may fluoresce. In other embodiments only a front portion may fluoresce. Still other embodiments different areas of the matrix 64 may fluoresce.
  • a sample aliquot is moved, such as by pumping action, from the sample chamber into the chamber 56 containing the solid phase labeled antibody.
  • a sample aliquot is moved, such as by pumping action, from the sample chamber into the chamber 56 containing the solid phase labeled antibody.
  • no sample would flow and the process described below could not occur.
  • the labeled antibody is thoroughly mixed with the sample using precision pumped flow through a mixing matrix.
  • the resulting mixture is pumped to a flow channel 60 wherein it is flowed under the control of the fluid moving source at a precise rate so as to control binding of the analyte contained in the sample with the labeled antibody.
  • the channel is sized so that the mixture would not flow through this channel.
  • the fluid flows rapidly into the mixing chamber 56 and flows slower in the chamber itself (but at a faster rate than it flows down the open channel 60).
  • the fluid flowing through the channel 60 is the time when the antigen in the sample is binding to the labeled antibody. This is controlled precisely to allow for adequate incubation time. It flows at a very slow rate through the precision flow channel 60. In one embodiment of the present invention, the flow rate is about 2-15 ul/sec
  • the mixture upon exiting the precision flow channel 60, the mixture is forced by the fluid moving source into a flow control chamber 62 wherein further mixing occurs due to the turbulent flow to assure homogeneity.
  • this chamber 62 is constructed in such a way so as to also force the flow of the reacted mixture into the portion of the flow-cell containing an immobilized antibody on a high surface area matrix.
  • the reacted mixture flows through the matrix 64 in intimate contact with materials therein, such as but not limited to immobilized antibody.
  • materials therein such as but not limited to immobilized antibody.
  • the analyte in the sample which has bound to the labeled antibody during the precision flow step additionally becomes bound to the immobilized antibody.
  • Further sample, essentially free from any labeled material is then forced through the matrix to reduce any non-specific binding in the fluorescence zone.
  • This excess mixed and unmixed sample is moved, such as by pumping action, into an empty sample overflow chamber. In some embodiments, without the fluid moving source, the washing and flow into the sample overflow chamber would not occur.
  • This fluid moving source, induced flow process produces a detectable intensity level of fluorescence when illuminated by the proper wavelength of light through the material covering all four sides of the fluorescent zone.
  • the pump pressure is sufficient to maintain a flow rate through the fluorescent zone can be about 0.5 -5 cm/min.
  • At least one side of the fluorescent area 72 is covered by a clear window. The intensity of this fluorescence is measured through the window and compared to the intensity produced by this process using know concentrations of the analyte. Comparison with the unknown sample's intensity allows quantization of the level of analyte it contains, hi one embodiment, the fluorescence area is contained on all four sides to function as described and the label is invisible without specialized optics.
  • the flow control chamber 62 will break any possible capillary attraction since it is much larger than an area that the flow would usually bridge and can depend on the liquid and wettability of the surface.
  • Flow control chamber 62 is dimensionally larger than an area that supports capillary flow regardless of the liquid and wettability of the surface of flow control chamber 62.
  • flow control chamber is 1-10 mm deep Additionally, the flow control chamber 62 functions to mix conjugate (presumably bound to antigen in the sample) before it enters the immobilized antibody area. It also allows for fluid to be forced into portions of the matrix 64 that overhang the chamber 62, since that may provide a greater exposed area for fluid contact.
  • One challenge of the present invention involves flowing fluid from an open channel into a partially occluded area (holding the immobilized antibody).
  • the chamber 62 as described above, may be used to address this challenge.
  • the use of flow control chamber 62 is one method to force liquid into the occluded area (which may be a hydrophobic material).
  • a matrix like polypropylene may be used and that creates a blockage of flow. Fluid is forced in the matrix to interact with the immobilized antibody.
  • the chamber 62 exposes a greater surface area of the matrix, allowing for forcing into the matrix 64. Since the area is sealed, unlike most lateral flow devices, pressure may be exerted to force fluid into the matrix 64. The overhang of the matrix 64 provides greater surface on which pressure may be exerted.
  • Flow control chamber will depend on selection of the media.
  • Some embodiments of the present invention may eliminate the conjugate matrix 58 and chamber 56.
  • the chamber 56 could, instead, be part or area of larger cartridge where conjugate is introduced and mixed with sample. The mixture may then be flowed directly to the precision flow channel.
  • the present invention may have a mixing chamber that is not part of the flow cell and part of another device.
  • Figure 3 provides a perspective view of a top surface of the flow cell 100.
  • the flow cell 100 includes a precision flow channel 102 which leads to an immobilized antibody chamber 104.
  • the chamber 104 in other embodiments, may contain other materials besides antibody, for detecting analytes.
  • the chamber 104 will allow fluid to flow into sample overflow chamber 106.
  • Figure 4 shows a cross-sectional view of the embodiment shown in Figure 3.
  • sample fluid enters at location 108. It flows into a mixing chamber 110.
  • the mixing chamber 110 may be a vortex mixing chamber.
  • Other embodiments may use chambers of other geometries or cross sections such as oval, round, triangular, rectangular, polygonal or any single or multiple combinations of the above.
  • the mixing chamber 110 may have dry reagent or other material that is located along a portion 112 of the chamber 110. In some embodiments, the reagent may be sprayed on to the surface of the chamber 110. Other embodiments may use layers adhered to the chamber 110. Other may have the entire chamber surface coated with reagent or label. Other embodiments may have geometric patterns on the surface of chamber 110. Geometries such as oval, round, triangular, rectangular, polygonal or any single or multiple combinations of the above may be used.
  • sample fluid will only enter the flow channel 102 when the level in the mixing chamber 110 rises to a sufficient height.
  • the incubation with the analyte in the sample and the label may occur.
  • the mixture then passes to the immobilized antibody chamber 104.
  • the immobilized antibody in chamber 104 is located only on the top surface 114 of the chamber. This is particularly useful if whole blood is used with flow cell 100. Since the cells in whole blood can freely pass through the open, non-capillary, dimensions of the flow cell 100, whole blood can be used directly as the sample without cell removal or lysis. None-the-less by immobilizing the antibody at the top of the chamber relative to gravity, only plasma is present in the antibody binding zone due to microscopic settling of the blood cells as they are moved slowly by fluid moving source through the precision flow channel.
  • This embodiment shows a device with a direct injection port 130 and a label injection port 132.
  • This embodiment allows for introduction of flow to cause mixing. This ability to introduce multiple flows allows for creating a variety of sequential flow options.
  • a wash buffer may be flowed via the direct injection port 130 to remove sample/label completely and by so doing reduce background interferences.
  • the sample is flowed directly into the immobilized antibody chamber 134 through the direct injection port 130.
  • a buffer is pumped through the label mixing chamber and carries the label through the label injection port 132 into the immobilized antibody chamber.
  • sample is flowed directly into the immobilized antibody chamber 134 through the direct injection port 130.
  • a buffer is moved through the label mixing chamber and carries the label through the label injection port 132 into the immobilized antibody chamber.
  • Apparatus 10 is used for a sandwich of HCG assay.
  • the HCG is obtained from serum, plasma or urine in a volume of 10 to 100 microliters.
  • the label is monoclonal or polyclonal antibody and is conjugated to the flurophore Texas Red at a ratio between 1-7 of flurophore per antibody.
  • the label is directed to the beta subunit of HCG. 5-500 micrograms of label are utilized.
  • Anti HCG antibody, to the alpha subunit, is immobilized in measurement chamber 19.
  • Flow channel 60 has a volume of from 5 -200 microliters.
  • Apparatus 10 is used for the cardiac test marker NT pro-BNP in a sandwich assay.
  • the NT pro-BNP is obtained from serum or plasma, with the cells being separated from whole blood, in a volume of 20 to 200 microliters.
  • Anti-NT pro-BNP antibody is the conjugate and is covalently coupled to polystryene beads that incorporate a deep red fluorescent dye in the 50 microgram to 1 milligram range of dried material.
  • Flow channel 60 has a volume of 100 - 400 microliters.
  • Anti-NT pro-BNP is immobilized in measurement chamber 19.
  • Apparatus 10 is used in a competitive assay for digoxin.
  • the digoxin is from serum, plasma or saliva, in a volume of 10 to 50 microliters .
  • Anti-digoxin is the immobilized conjugate with deep red fluorescent beads in a total amount of antibody approximately equal on a molar basis to 1 A of the maximum digoxin expected in the sample.
  • Flow channel 60 has a volume of 50 to 300 microliters.
  • Measurement chamber 19 includes immobilized digoxin which captures any excess, unreacted label..
  • Apparatus 10 is used in a competitive assay for theophylline.
  • the theophylline is from serum, plasma or saliva in a volume of 500 nanoliters to 5 microliters.
  • the immobilized conjugate used is theophylline coupled to Texas Red at a molar ratio less than the minimum detection limit desired in the assay.
  • Flow channel 60 has a volume of 0 to 50 microliters.
  • Measurement chamber 19 includes immobilized anti-theophylline antibody which captures the labeled and unlabeled theophylline in proportion to their relative ratios.
  • Apparatus 10 is used for a sandwich CK-MB assay.
  • the CK-MB is obtained from serum or plasma in a volume of 20 to 200 microliters.
  • Anti-CK-MB is conjugated to gold sol at a ratio between 1-4 gold sol to antibody.
  • the label is directed to the B subunit of CK-MB. 10-500 micrograms of label are utilized.
  • Anti CK-MB antibody, to the M subunit, is immobilized in measurement chamber 19.
  • Flow channel 60 has a volume of from 50 -500 microliters.
  • a refiectometer is used to determine the amount of CK-MB in the sample EXAMPLE 6
  • Apparatus 10 is used for an assay of anti HIV antibody.
  • the volume of serum, plasma or saliva used is 5 to 100 microliters .
  • the label is an HIV peptide conjugated to Texas Red at a total amount invisible to unaided visual detection.
  • the mixture passes through flow channel 60 that has a volume of 25 to 250 microliters.
  • Measurement chamber 19 includes immobilized protein A which captures the antibody/label complex.
  • Apparatus 10 is used for an assay of HbsAg.
  • the HbsAg is obtained from serum, saliva or plasma, in volume of 20 to 200 microliters.
  • Anti-HbsAg antibody is the conjugate and is covalently coupled to polystryene beads that incorporate a deep red fluorescent dye in the 50 microgram to 1 milligram range of dried material.
  • Flow channel 60 has a volume of 100 - 400 microliters.
  • Anti-HbsAg is immobilized in measurement chamber 19 to capture the HsAg/label complex. A final wash of buffer is utilized to reduce background and enhance sensitivity.
  • Apparatus 10 is used for an assay of HbsAg surface antigen.
  • the HbsAg is obtained from serum or plasma, with the cells being separated from whole blood, in an amount of 20 to 200 microliters.
  • Anti-HbsAg antibody is the conjugate and is covalently coupled to polystryene beads that incorporate a deep red fluorescent dye in the 50 microgram to 1 milligram range of dried material.
  • Flow channel 60 has a volume of 100 - 400 microliters.
  • Anti-HbsAg is immobilized in measurement chamber 19. A final wash of buffer is utilized.
  • FIG. 7 a still further embodiment of a flow cell 150 will now be described.
  • This embodiment discloses a precision flow channel 152 leading to a matrix 154 which may hold an immobilized antibody.
  • the fluorescence area 156 may span the entire matrix 154. Or in some embodiments it may span particular areas.
  • the matrix 154 is similar to that described in Figure 2 and fluid flows through the matrix instead of over it.
  • Figure 8 shows a cross-sectional view of the device of Figure 7.
  • the flow cell 150 may have a vortex mixing chamber 158. Dried label or other material may be on the surface of chamber 158 and mixed with sample fluid in the chamber. Fluid will then flow through the precision flow channel 152 at a flow rate sufficient to provide the desired incubation.
  • the present embodiment may optionally include the flow control chamber 160 to provide further mixing and to allow greater exposure to the surface area of the matrix 154.
  • the chamber may be located to extend over or above the matrix 154.
  • a sample overflow chamber 162 is provided to allow for fluid to drain therein.
  • a forced flow assay device 210 for the detection of an analyte concentration in a sample.
  • the assay device 210 includes an inlet 212 for receiving a sample containing an analyte.
  • At least one flow channel 214 is in fluid communication with the inlet 212.
  • the flow channel 214 has at least one reagent area 216 with a labeled binding partner.
  • the flow channel 214 is dimensioned to provide an incubation period for reacting an effective amount of labeled binding partner with the sample analyte to form an analyte-label conjugate.
  • the flow can be stopped and restarted in order to provide for total reaction (incubation) which can be provided by a control element at a pump coupled to the flow channel 214.
  • the flow channel 214 is 1 mm or less in width and provide a flow of no great than 1 microliter/sec.
  • a detection zone 218 is in fluid communication with the flow channel 214.
  • the detection zone 218 has at least one capture area 220 that is homogeneously saturated with a binding moiety.
  • the detection zone 218 is dimensioned to provide a wide assay range of enhanced sensitivity.
  • Figure 10 illustrates an embodiment with multiple capture areas 220.
  • the capture area 220 can include a matrix homogeneously saturated with the binding moiety.
  • the binding moiety can be directly immobilized onto a portion of the flow channel 214.
  • the matrix can immobilized in the capture area 220 in a manner effective to provide an assay that is capable of detecting the entire dynamic range of the sample analyte. This can be achieved by providing that the detection zone 218 has a capture area 220 which spans the width of the test strip therein.
  • the binding moiety is provided in area at least about 4 mm to at least 6 mm wide and about 4 mm to at least about 6 mm in length. Further lengthening can result in greater differentiation and dynamic ranges. Due to the larger area of the capture area, the density of the capture reagent immobilized thereon is increased.
  • sample analyte-label conjugate migrates along the length of the capture area 220, it is sequentially bound to any unreacted capture reagent. Consequently, more analyte will be required to saturate the immobilized binding moiety.
  • the assay device 210 can have a recessed portion located within the flow channel 214 that is upstream from the detection zone 218. This creates turbulent flow for homogenous mixing of sample analyte and label reagent.
  • AIl or a portion of the length of the capture area 220 is in optical communication with a detector 222 for detection. Suitable detectors 222 include but are not limited to a, spectrophotometer, reflectometer, fluorometer a, spectrophotometer, reflectometer, fiuorometer, luminometer, time resolved fluorometer and the like.
  • a fluid control device 224 provides forced fluid flow throughout the assay device 210.
  • the fluid control device 224 can be a variety of device, including but not limited to, a positive displacement pump, vacuum pump, and the like.
  • a method for extending the dynamic range of detection of analyte using a solid-phase assay.
  • Samples each with a known analyte-label conjugate concentration, are reacted with at least one capture area 220 in the detection zone 218 on a solid support.
  • the capture area 220 is homogeneously saturated along the length and width dimensions with a known amount of the binding moiety. All or part of the length of the capture area 220 with the detector 222 produces a series of intensity signals corresponding to the immobilized analyte-label conjugate unique to the concentration of analyte in each sample.
  • a continuous dose response curve is produced from the unique series of detection signals for each of the immobilized sample analyte-label conjugate concentrations. This is plotted against the integrated position on the capture area 220. An overall assay response value is then calculated for each continuous dose response curve. Overall assay response values are plotted against the known analyte-label conjugate concentrations to create a calibration curve. The concentration of an analyte in a test sample containing an unknown concentration analyte is ascertained by determining where the test sample assay response falls on the calibration curve. At least one capture area 220 is dimensioned to capture the sample analyte-label conjugate with the binding moiety present. This is in an amount effective to immobilize any unbound analyte- label conjugate until the series of detection signals decrease substantially below the observed horizontal asymptote of the continuous dose response curve. This provides enhanced assay sensitivity.
  • Figure 11 is illustrates a series of curves indicating what happens as saturation is reached. Because the 10,000 pg/ml intensity is saturated, the intensity difference between the 5,000 and 10,000 point is small. However, the maximum signal is maintained over more positions with-in the scan, i.e. it is flat topped instead of peaked. Greater differentiation can thus be achieved using software to predict a peak height without the physical saturation limit or the area under the curves can be used in lieu of simple peak height. Either method results in a continuous function calibration curve useful over a broader range than peak height alone. While the invention is susceptible to various modifications and alternative constructions, certain illustrated embodiments thereof are shown in the drawings and have been described above in detail.
  • the present invention addresses the incubation issue with a fluid moving source as opposed to a timer or a membrane that conducts fluid at a certain rate.
  • Some embodiments may have a thicker membrane and then an end-on flow without substantial overhang of the matrix may be used.
  • the membrane may be 10 times thicker than non end-on embodiments.
  • some embodiments of the matrix may use porous plastics material, such as polypropylene, polyethylene (preferably of very high molecular weight), polyvinylidene fluoride, ethylene vinylacetate, acrylonitrile and polytetrafluoro-ethylene can be used. It can be advantageous to pre-treat the member with a surface-active agent during manufacture, to reduce hydrophobicity. Porous sample receiving members can also be made from paper or other cellulose materials, such as nitro-cellulose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optical Measuring Cells (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)

Abstract

L'invention porte sur un appareil d'analyse de prélèvements liquides comprenant un capteur, qui peut être une source de lumière, dirigé vers une cellule de flux et un photocapteur qui détecte un faisceau lumineux réfléchi par la cellule de flux. Le photocapteur surveille le liquide dans la cellule de flux en détectant le faisceau lumineux réfléchi par la cellule de flux, et surveille de la sorte le processus d'analyse. La cellule de flux comprend un canal d'écoulement qui permet au prélèvement liquide de s'écouler avec un débit tel qu'une incubation suffisante du liquide se produit avant que le liquide ne pénètre dans une zone où les niveaux d'analyte seront détectés.
EP05811958A 2004-10-12 2005-10-12 Appareil et procede de dosage a ecoulement lateral de precision Withdrawn EP1805501A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61827804P 2004-10-12 2004-10-12
US10/990,762 US20060079003A1 (en) 2004-10-12 2004-11-16 Apparatus and method for a precision flow assay
US10/991,331 US20060078471A1 (en) 2004-10-12 2004-11-16 Apparatus and method for a precision flow assay
PCT/US2005/037122 WO2006042332A2 (fr) 2004-10-12 2005-10-12 Appareil et procede de dosage a ecoulement lateral de precision

Publications (1)

Publication Number Publication Date
EP1805501A2 true EP1805501A2 (fr) 2007-07-11

Family

ID=36149045

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05811958A Withdrawn EP1805501A2 (fr) 2004-10-12 2005-10-12 Appareil et procede de dosage a ecoulement lateral de precision

Country Status (2)

Country Link
EP (1) EP1805501A2 (fr)
WO (1) WO2006042332A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2439530B1 (fr) 2008-03-14 2013-11-06 Scandinavian Micro Biodevices ApS Système microfluidique pour des tests de coagulation ou des tests de agglutination
US10145842B2 (en) 2012-04-11 2018-12-04 Quidel Cardiovascular Inc. Microfluidic device, system and method
MX2017007576A (es) 2014-12-12 2018-03-09 Opko Diagnostics Llc Sistemas fluídicos que comprenden un canal de incubación, que incluye sistemas fluídicos formados por moldeo.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451619B1 (en) * 1994-06-29 2002-09-17 Inverness Medical Switzerland Gmbh Monitoring methods and devices for use therein
US20030175992A1 (en) * 1999-09-10 2003-09-18 Anthony Toranto Glucose assay
US6436722B1 (en) * 2000-04-18 2002-08-20 Idexx Laboratories, Inc. Device and method for integrated diagnostics with multiple independent flow paths
US7879293B2 (en) * 2001-09-28 2011-02-01 Orasure Technologies, Inc. Sample collector and test device
US6673617B2 (en) * 2002-03-14 2004-01-06 Lifescan, Inc. Test strip qualification system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006042332A2 *

Also Published As

Publication number Publication date
WO2006042332A3 (fr) 2006-09-28
WO2006042332A2 (fr) 2006-04-20

Similar Documents

Publication Publication Date Title
US7189573B2 (en) Apparatus and method for process monitoring
CA1310566C (fr) Element et methode pour effectuer des bio-essais de facon precise, rapide et simple
US8835184B2 (en) Analysis system
JP4571129B2 (ja) 反応試薬区域に流体を均一に塗布する方法
US4623461A (en) Transverse flow diagnostic device
US4918025A (en) Self contained immunoassay element
EP1816479A1 (fr) Capteur
EP2610618A1 (fr) Dispositif microfluidique centrifuge et procédé de détection d'analytes dans un échantillon liquide
US20110008776A1 (en) Integrated separation and detection cartridge using magnetic particles with bimodal size distribution
WO2012075251A1 (fr) Dispositif de mesure d'échantillons et dispositif d'analyse avec dilution d'échantillon intégrée
WO2012075256A2 (fr) Dispositif doseur d'échantillon et dispositif d'analyse comportant la dilution intégrée de l'échantillon
US20060078471A1 (en) Apparatus and method for a precision flow assay
US20040096985A1 (en) Specific binding analyzer and method of analyzing specific binding
CN111013677B (zh) 微流控芯片、检测装置以及检测方法
MX2011010586A (es) Dispositivo y procedimiento para la verificacion y para el analisis cuantitativo de analitos, particularmente de micotoxinas.
US20060079003A1 (en) Apparatus and method for a precision flow assay
EP1805501A2 (fr) Appareil et procede de dosage a ecoulement lateral de precision
JP3654591B2 (ja) 特異結合分析方法および特異結合分析デバイス
TWI295730B (en) Microfluidic chip for sample assay and method thereof
JP4471687B2 (ja) 生化学分析方法と生化学分析装置
JPH0961312A (ja) 簡易測定装置
JP6190472B2 (ja) 新規のＰｏＣ検査システムおよび方法
US20240183846A1 (en) Method for analyzing liquid immune response using magnetic beads
IE20080745A1 (en) An analysis system
JP2001264325A (ja) 乾式分析素子

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070510

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FASTRAQ, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WITTY, THOMAS, R.

Inventor name: CASE, ROBERT

Inventor name: CASTANON, SCOTT

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20090701